Skip Navigation
Skip to contents

KDDW 2025


Scientific Program

Home    >    Program    >    Scientific Program

Member Societies

검색

Symposium 01: Distinguished papers of 2024–2025 in Clinical and Molecular Hepatology English

Date / Time Nov. 13 (Thu), 09:00-10:30
Room Vista 1
Chair(s) Yoon Jun Kim (Seoul National University, Korea)
Hyung Joon Kim (Chung-Ang University, Korea)
Speakers 09:00-09:10 The CMH journey: Global growth and author guidance Yeonjung Ha (CHA University, Korea)
09:10-09:30 CMH clinical research highlight–Dynamic analysis of acute deterioration in chronic liver disease patients using modified quick sequential organ failure assessment Do Seon Song (The Catholic University of Korea, Korea)
09:30-09:50 CMH clinical trial highlight–Antiviral therapy for chronic hepatitis B with mildly elevated aminotransferase: A rollover study from the TORCH-B trial Yao-Chun Hsu (I-Shou University, Taiwan)
09:50-10:10 CMH epidemiologic research highlight–Extrahepatic malignancies and antiviral drugs for chronic hepatitis B: A nationwide cohort study Jeong-Hoon Lee (Seoul National University, Korea)
10:10-10:30 CMH multinational research highlight–Carvedilol to prevent hepatic decompensation of cirrhosis in patients with clinically significant portal hypertension stratified by new non-invasive model (CHESS2306) Xiaolong Qi (Southeast University, China)

Presidential Lecture: Chung Yong Kim memorial lecture Korean

Date / Time Nov. 13 (Thu), 10:50-12:20
Room Vista 1
Chair(s) Sook-Hyang Jeong (Seoul National University, Korea)
Speakers 10:50-12:20 The liver odyssey: Four decades of progression and hope Joong-Won Park (Myongji Hospital, Korea)

Symposium 09: Special considerations for liver diseases in distinct conditions English

Date / Time Nov. 13 (Thu), 13:20-14:50
Room Vista 1
Chair(s) Young-Suk Lim (University of Ulsan, Korea)
Ji Hoon Kim (Korea University, Korea)
Speakers 13:20-13:42 Risk-stratified prophylaxis for HBV reactivation in patients receiving biological agents Pin-Nan Cheng (National Cheng Kung University, Taiwan)
13:42-14:04 Management of anti-HBc or HBsAg-positive donors and recipients in liver transplantation Deok Gie Kim (Yonsei University, Korea)
14:04-14:26 Risks and benefits of statins and DOACs in cirrhotic patients with cardiovascular disease Ho Soo Chun (Ewha Womans University, Korea)
14:26-14:48 Current controversies in HCC risk and surveillance after SVR in HCV-infected patients Ryosuke Tateishi (The University of Tokyo, Japan)
14:48-14:50 Q&A

Symposium 13: Big data in hepatology research: Sources and applications English

Date / Time Nov. 13 (Thu), 15:10-16:40
Room Vista 1
Chair(s) Si Hyun Bae (The Catholic University of Korea, Korea)
Sang Hoon Ahn (Yonsei University, Korea)
Speakers 15:10-15:32 Korean nationwide population-based study using the National Health Information Database Han Ah Lee (Chung-Ang University, Korea)
15:32-15:54 Taiwanese nationwide database for chronic viral hepatitis Mei-Hsuan Lee (National Yang Ming Chiao Tung University, Taiwan)
15:54-16:16 Common data models for real-world data analysis Rae Woong Park (Ajou University, Korea)
16:16-16:38 The genetic architecture of hepatocellular carcinoma: Insights from genome-wide association studies Eric Trepo (Universite Libre de Bruxelles, Belgium)
16:38-16:40 Q&A

Symposium 17: Optimizing treatment strategies for HCC: Concurrent and sequential approaches English

Date / Time Nov. 14 (Fri), 08:30-10:00
Room Vista 2
Chair(s) Han Chu Lee (University of Ulsan, Korea)
Jae Young Jang (Soonchunhyang University, Korea)
Speakers 08:30-08:52 The priority decision for subsequent systemic therapy after first-line failure of ICI-based regimens for HCC Arndt Vogel (University of Toronto, Canada)
08:52-09:14 Liver-directed therapy combined with IO/TKI for locally advanced and metastatic HCC Zhen-Wei Peng (Sun Yat-sen University, China)
09:14-09:36 Role of radiotherapy for advanced-stage HCC in the era of IO Jeong Il Yu (Sungkyunkwan University, Korea)
09:36-09:58 Efficacy and safety of ICI-based treatment for Child-Pugh B HCC Jean-Charles Nault (Université Sorbonne Paris Nord, France)
09:58-10:00 Q&A

Symposium 22: In vitro and in vivo experimental models to study liver diseases Korean

Date / Time Nov. 14 (Fri), 10:20-11:50
Room Vista 2
Chair(s) Jung-Hwan Yoon (Seoul National University, Korea)
Won-Il Jeong (KAIST, Korea)
Speakers 10:20-10:50 Models for hepatitis B and the associated liver cancers Kyun-Hwan Kim (Sungkyunkwan University, Korea)
10:50-11:20 Preclinical MASH studies Sang Geon Kim (Dongguk University, Korea)
11:20-11:50 Cancer immunotherapy research Tae-Jin Kim (Korea Institute of Radiological & Medical Sciences, Korea)

Symposium 27: Biomarkers for diagnosis, treatment response, and prognosis in liver diseases English

Date / Time Nov. 14 (Fri), 13:20-14:50
Room Vista 2
Chair(s) Jia-Horng Kao (National Taiwan University, Taiwan)
Moon Seok Choi (Sungkyunkwan University, Korea)
Speakers 13:20-13:42 Early predictors of hepatitis B relapse after antiviral cessation Cheng-Hao Tseng (I-Shou University, Taiwan)
13:42-14:04 Biomarkers for monitoring disease progression in MASLD Nabuharu Tamaki (Red Cross Hospital Tokyo, Japan)
14:04-14:26 Imaging markers predicting response to IO in HCC Subin Heo (University of Ulsan, Korea)
14:26-14:48 Histological markers for differential diagnosis of liver tumors and inflammatory conditions Haeryoung Kim (Seoul National University, Korea)
14:48-14:50 Q&A

PG Course 04: Guidelines and evidence-based recommendations in liver disease management Korean

Date / Time Nov. 14 (Fri), 15:10-16:40
Room Grand 1
Chair(s) Neung Hwa Park (University of Ulsan, Korea)
Sungbum Cho (Chonnam National University, Korea)
Speakers 15:10-15:32 Chronic hepatitis B: Antiviral strategy Won-Mook Choi (University of Ulsan, Korea)
15:32-15:54 Chronic hepatitis C: Antiviral strategy Young Kul Jung (Korea University, Korea)
15:54-16:16 MASLD: Current and potential new treatments Won Sohn (Sungkyunkwan University, Korea)
16:16-16:38 Liver cirrhosis: Complications and specific management Do Seon Song (The Catholic University of Korea, Korea)
16:38-16:40 Q&A
Supported by Member Societies
Associated Society
Diamond
  • 대웅제약
Platinum
Gold
Silver
Bronze
  • 중외제약
  • 부광약품

Go to Top

케이디디더블유 운영협의체

Business License No.: 609-82-84671

President: Joo-Sung Kim

E-mail : kddwoffice@gmail.com

Address : 2F, 30, Bamgogae-ro 1-gil, Gangnam-gu, Seoul, 06349, Republic of Korea
KDDW 2025 Secretariat
Contact (Scientific Program & Abstract)
Email. kddwinfo@medioffice.or.kr / Tel. +82-10-2334-8265
(Registration & Sponsor)
Email. kddwconference@medioffice.or.kr / Tel. +82-2-459-8266